CD19 and neoplasm: Furthermore, TriBAFF/CD3/ABDCon triggered rapid T-cell cytokine release (2 h post-injection) that maintained tumor suppression with superior serum cytokine production compared to CD19 CAR-T cells (Fig. S15D).